Cellular and molecular mechanisms of bleomycin-induced murine scleroderma: Current update and future perspective

Experimental Dermatology

Volumn 14, Issue 2, 2005, Pages 81-95

  Yamamoto, Toshiyuki ^a   Nishioka, Kiyoshi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Bleomycin; Mouse model; Scleroderma

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BLEOMYCIN; CD40 ANTIGEN; CONNECTIVE TISSUE GROWTH FACTOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; CELL ADHESION; CELL INTERACTION; EXTRACELLULAR MATRIX; FIBROBLAST; HISTOPATHOLOGY; INFLAMMATORY CELL; LYMPHOCYTIC INFILTRATION; MACROPHAGE ACTIVATION; MAST CELL; MOLECULAR MECHANICS; MOUSE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; SCLERODERMA; T LYMPHOCYTE;

ANIMALS; BLEOMYCIN; CELL ADHESION; CHEMOKINES; CYTOKINES; DISEASE MODELS, ANIMAL; EOSINOPHILS; EXTRACELLULAR MATRIX; FIBROBLASTS; HUMANS; INFLAMMATION; MACROPHAGES; MAST CELLS; MICE; MODELS, BIOLOGICAL; OXIDATIVE STRESS; SCLERODERMA, SYSTEMIC; SKIN; T-LYMPHOCYTES;

EID: 14044268846     PISSN: 09066705     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0906-6705.2005.00280.x     Document Type: Review

References (153)

1. Krieg T, Meurer M. Systemic scleroderma. Clinical and pathophysiological aspects. J Am Acad Dermatol 1988: 18: 457-481.
2. Mauch C, Eckes B, Hunzelmann N, Oono T, Kozlowska E, Krieg T. Control of fibrosis in systemic scleroderma. J Invest Dermatol 1993: 100: 92-96.
3. Fleischmajer R, Perlish J S, Reeves J R T. Cellular infiltrates in scleroderma skin. Arthritis Rheum 1977: 20: 975-984.
4. Scharffetter K, Lankat-Buttgereit B, Krieg T. Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization. Eur J Clin Invest 1988: 18: 9-17.
5. Green L D, Sweet H O, Bunker L E. Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton. Am J Pathol 1976: 82: 493-507.
6. Christner P J, Peters J, Hawkins D, Siracusa L D, Jimenez S A. The tight skin 2 mouse: an animal model of scleroderma displaying cutaneous fibrosis and mononuclear cell infiltration. Arthritis Rheum 1995: 38: 1791-1798.
7. Van De Water J, Gershwin M E. Avian scleroderma. An inherited fibrotic disease of White Leghorn chicken resembling progressive systemic sclerosis. Am J Pathol 1986: 120: 478-482.
8. Gruschwitz M S, Moormann S, Kromer G et al. Phenotypic analysis of skin infiltrates in comparison with peripheral blood lymphocytes, spleen cells and thymocytes in early avian scleroderma. J Autoimmun 1991: 4: 577-593.
9. Jaffee B D, Claman H N. Chronic graft-versus-host-disease (GVHD) as a model for scleroderma. I. Description of model system. Cell Immunol 1983: 73: 1-12.
10. Claman H N, Jaffee B D, Huff J C, Clark R A F. Chronic graft-versus-host disease as a model for scleroderma. II. Mast cell depletion with deposition of immunoglobulins in the skin and fibrosis. Cell Immunol 1985: 94: 73-84.
11. Mccormick L L, Zhang Y, Tootell E, Gilliam A C. Anti-TGF-β treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol 1999: 163: 5693-5699.
12. Ruzek MC, Jha S, Ledbetter S, Richards S M, Garman R D. A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease. Arthritis Rheum 2004: 50: 1319-1331.
13. Umezawa H, Maeda K, Takeuchi T, Okami Y. New antibiotics, bleomycin A and B. J Antibiot 1966: 19: 200-209.
14. Remlinger K A. Cutaneous reactions to chemotherapy drugs. The art of consultation. Arch Dermatol 2003: 139: 77-81.
15. Westergren-Thorsson G, Hernnas J, Sarnstrand B, Oldberg A, Heinegard D, Malmstrom A. Altered expression of small proteoglycans, collagen, and transforming growth factor-β1 in developing bleomycin-induced pulmonary fibrosis in rats. J Clin Invest 1993: 92: 632-637.
16. Raghow R, Lurie S, Seyer J M, Kang A H. Profiles steady state levels of messenger RNAs coding for type I procollagen, elastin, and fibronectin in hamster lungs undergoing bleomycin-induced interstitial pulmonary fibrosis. J Clin Invest 1985: 76: 1733-1739.
17. Clark J C, Starcher B C, Uitto J. Bleomycin-induced synthesis of type I procollagen by human lung skin fibroblasts in culture. Biochim Biophys Acta 1980: 631: 359-370.
18. Yamamoto T, Eckes B, Krieg T. Bleomycin increases steady-state levels of type I collagen, fibronectin and decorin gene expression in human skin fibroblasts. Arch Dermatol Res 2000: 292: 556-561.
19. Sterling K M Jr, DiPetrillo T A, Kotch J P, Cutroneo K R. Bleomycin-induced increase of collagen turnover in IMR-90 fibroblasts: an in vitro model of connective tissue restructuring during lung fibrosis. Cancer Res 1982: 42: 3502-3506.
20. Denholm E M, Phan S H. The effects of bleomycin on alveolar macrophage growth factor secretion. Am J Pathol 1989: 134: 355-363.
21. Yamamoto T, Katayama I, Nishioka K. Fibroblast proliferation by bleomycin stimulated peripheral blood mononuclear cell factors. J Rheumatol 1999: 26: 609-615.
22. Mountz J D, Downs Minor M B, Turner R, Thomas M B, Richards F, Pisko E. Bleomycin-induced cutaneous toxicity in the rat: analysis of histopathology and ultrastructure compared with progressive systemic sclerosis (scleroderma). Br J Dermatol 1983: 108: 679-686.
23. Yamamoto T, Takagawa S, Katayama I et al. Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999: 112: 456-462.
24. Yamamoto T, Takahashi Y, Takagawa S, Katayama I, Nishioka K. Animal model of sclerotic skin. II: Bleomycin induced scleroderma in genetically mast cell deficient WBB6F1-W/WV mice. J Rheumatol 1999: 26: 2628-2634.
25. Yamamoto T, Kuroda M, Takagawa S, Nishioka K. Animal model of sclerotic skin. III: Histopathological comparison of bleomycin-induced scleroderma in various mice strains. Arch Dermatol Res 2000: 292: 535-541.
26. Yamamoto T, Nishioka K. Animal model of sclerotic skin. IV: Induction of dermal sclerosis by bleomycin is T cell independent. J Invest Dermatol 2001: 117: 999-1001.
27. Yamamoto T, Nishioka K. Animal model of sclerotic skin. V: Increased expression of a-smooth muscle actin in fibroblastic cells in bleomycin-induced scleroderma. Clin Immunol 2002: 102: 77-83.
28. Yamamoto T, Nishioka K. Animal model of sclerotic skin. VI: Evaluation of bleomycin-induced skin sclerosis in nude mice. Arch Dermatol Res 2004: 295: 453-456.
29. Sappino A-P, Masouye I, Saurat J-H, Gabbiani G. Smooth muscle differentiation in scleroderma fibroblastic cells. Am J Pathol 1990: 137: 585-591.
30. Kirk T Z, Mark M E, Chua C C, Chua B H, Mayers M D. Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1. J Biol Chem 1995: 270: 3423-3428.
31. Serini G, Gabbiani G. Modulation of alpha-smooth muscle actin expression in fibroblasts by transforming growth factor-β isoforms: an in vivo and in vitro study. Wound Repair Regen 1996: 4: 278-287.
32. Bostrom H, Willetts K, Pekny M et al. PDGF-A signaling is a critical event in lung alveolar myofibroblasts development and alveogenesis. Cell 1996: 85: 863-873.
33. Wallace V A, Kondo S, Kono T et al. A role for CD4+ T cells in the pathogenesis of skin fibrosis in tight skin mice. Eur J Immunol 1994: 24: 1463-1466.
34. Thrall R S, Lovett E J, Barton R W, McCormick J R, Phan S H, Ward P A. The effect of T cell depletion on the development of bleomycin induced pulmonary fibrosis in the rat. Am Rev Respir Dis 1980: 121: A99.
35. Szapiel S V, Elson N A, Fulmer J D, Hunninghake G W, Crystal R G. Bleomycin-induced interstitial pulmonary disease in the nude, athymic mouse. Am Rev Respir Dis 1979: 120: 893-899.
36. Schrier D J, Phan S H, McGarry B M. The effects of nude (nu/nu) mutation on bleomycin induced pulmonary fibrosis. A biochemical evaluation. Am Rev Respir Dis 1983: 127: 614-617.
37. Lake-Bullock M H V, Zhu J, Hao H, Cohen D A, Kaplan A M. T cell independence of bleomycin-induced pulmonary fibrosis. J Leukoc Biol 1999: 65: 187-195.
38. Kovacs E J. Fibrogenic cytokines: the role of immune mediators in the development of scar tissue. Immunol Today 1991: 12: 17-23.
39. Kraling B M, Maul G G, Jemenez S A. Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. Pathobiology 1995: 63: 48-56.
40. Ishikawa O, Ishikawa H. Macrophage infiltration in the skin of patients with systemic sclerosis. J Rheumatol 1992: 19: 1202-1206.
41. Zhang Y, Mccormick L L, Desai S R, Wu S, Gilliam A C. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol 2002: 168: 3088-3098.
42. Hawkins R A, Claman H N, Clark R A F, Steigerwald J C. Increased dermal mast cell populations in progressive systemic sclerosis: a link in chronic fibrosis? Ann Intern Med 1985: 102: 1182-1186.
43. Nishioka K, Kobayashi Y, Katayama I, Takijiri C. Mast cell numbers in diffuse scleroderma. Arch Dermatol 1987: 123: 205-208.
44. Walker M, Harley R, LeRoy E C. Inhibition of fibrosis in Tsk mice by blocking mast cell degranulation. J Rheumutol 1987: 14: 299-301.
45. Mori H, Kawada K, Zhang P, Uesugi Y, Sakamoto O, Koda A. Bleomycin-induced pulmonary fibrosis in genetically mast cell-deficient WBB6F1-W/Wv mice and mechanism of the suppressive effect of tranilast, an antiallergic drug inhibiting mediator release from mast cells, on fibrosis. Int J Arch Allergy Appl Immunol 1991: 95: 195-201.
46. Yamamoto T, Takagawa S, Nishioka K. Mast cell-independent increase of type I collagen expression in experimental scleroderma induced by bleomycin. Arch Dermatol Res 2001: 293: 532-536.
47. Yamamoto T, Takagawa S, Katayama I, Nishioka K. Anti-sclerotic effect of anti-transforming growth factor-β antibody in bleomycin-induced scleroderma. Clin Immunol 1999: 92: 6-13.
48. Gustafsson R, Fredens K, Nettelbladt O, Hallgren R. Eosinophil activation in systemic sclerosis. Arthritis Rheum 1991: 34: 414-422.
49. Zhang K, Gharaee-Kermani M, McGarry B, Remick D, Phan S H. TNF-alpha-mediated lung cytokine networking and eosinophil recruitment in pulmonary fibrosis. J Immunol 1997: 158: 954-959.
50. Zhang K, Flanders K S, Phan S H. Cellular localization of transforming growth factor-β expression in bleomycin-induced pulmonary fibrosis. Am J Pathol 1995: 147: 352-361.
51. Pincus S H, Ramesh K S, Wyler D J. Eosinophils stimulate fibroblast DNA synthesis. Blood 1987: 70: 572-574.
52. Birkland T P, Cheavens M D, Pincus S H. Human eosinophils stimulate DNA synthesis and matrix production in dermal fibroblasts. Arch Dermatol Res 1994: 286: 312-318.
53. Hao H, Cohen D A, Jennings C D, Bryson J S, Kaplan A M. Bleomycin-induced pulmonary fibrosis is independent of eosinophils. J Leukoc Biol 2000: 68: 515-521.
54. Terada N. Hamano N, Nomura T et al. Interleukin 13 and tumor necrosis factor-alpha synergistically induce eotaxin production in human nasal fibroblasts. Clin Exp Allergy 2000: 30: 348-355.
55. Huaux F, Liu T, McGarry B, Ullenbruch M, Xing Z, Phan S H. Eosinophils and T lymphocytes possess distinct roles in bleomycin-induced lung injury and fibrosis. J Immunol 2003: 171: 5470-5481.
56. Roberts A B, Sporn M B. The transforming growth factors. In: Sporn M B, Roberts A B, eds. Handbook of Experimental Pharmacology. Peptide Growth Factors and Their Receptors, Vol. 95. New York: Springer-Verlag, 1990: 419-472.
57. Obberghen-Schilling E V, Roche N S, Flanders K C, Sporn M B, Roberts A B. Transforming growth factor β1 positively regulates its own expression in normal and transformed cells. J Biol Chem 1988: 263: 7741-7746.
58. Roberts A B, Sporn M B, Assoian R K et al. Transforming growth factor type β: rapid induction of fibroblasts and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986: 83: 4167-4171.
59. Zhang Y, McCormick L L, Gilliam A C. Latency-associated peptide prevents skin fibrosis in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol 2003: 121: 713-719.
60. Breen E, Shull S, Burne S et al. Bleomycin regulation of transforming growth factor-β mRNA in rat lung fibroblasts. Am J Respir Cell Mol Biol 1992: 6: 146-152.
61. King S L, Lichtler A C, Rowe D W et al. Bleomycin stimulates proal(I) collagen promoter through transforming growth factor-β response element by intracellular and extracellular signaling. J Biol Chem 1994: 269: 13156-13161.
62. Oi M, Yamamoto T, Nishioka K. Increased expression of TGF-β1 in the sclerotic skin in bleomycin-'susceptible' mouse strains. J Med Dent Sci 2004: 51: 7-17.
63. Nakao A, Fujii M, Matsumura R et al. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest 1999: 104: 5-11.
64. Dong C, Zhu S, Wang T et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci USA 2002: 99: 3908-3913.
65. Takagawa S, Lakos G, Mori Y, Yamamoto T, Nishioka K, Varga J. Sustained activation of fibroblast transforming growth factor-β/Smad signaling in a murine model of scleroderma. J Invest Dermatol 2003: 121: 41-50.
66. Bradham D M, Igarashi A, Potter R L, Grotendorst G R. Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell Biol 1991: 114: 1285-1294.
67. Igarashi A, Okochi H, Bradham D M, Grotendorst G R. Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol Biol Cell 1993: 4: 637-645.
68. Frazier K, Williams S, Kothapalli D, Klapper H, Grotendorst G R. Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. J Invest Dermatol 1996: 107: 404-411.
69. Grotendorst G R, Okochi H, Hayashi N. A novel transforming growth factor beta response element controls the expression of connective tissue growth factor gene. Cell Growth Differ 1996: 7: 469-480.
70. Igarashi A, Nashiro K, Mikuchi K et al. Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J Invest Dermatol 1995: 105: 280-284.
71. Shi-wen X, Pennington D, Holmes A et al. Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis genes in systemic sclerosis. Exp Cell Res 2000: 259: 213-224.
72. Sato S, Nagaoka T, Hasegawa M et al. Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. J Rheumatol 2000: 27: 149-154.
73. Heldin C-H, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999: 79: 1283-1316.
74. Yamakage A, Kikuchi K, Smith E A, LeRoy E C, Trojanowska M. Selective upregulation of platelet-derived growth factor alpha receptors by transforming growth factor beta in scleroderma fibroblasts. J Exp Med 1992: 175: 1227-1234.
75. Gay S, Jones R E, Huang G, Gay R E. Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. J Invest Dermatol 1989: 92: 301-303.
76. Klareskog L, Gustafsson R, Scheynimus A, Hallgren R. Increased expression of platelet-derived growth factor type B receptors in the skin of patients with systemic sclerosis. Arthritis Rheum 1990: 33: 1534-1540.
77. Xue-yi Z, Jian-Zhong Z, Ping T, Sheng-Qing M. Expression of platelet-derived growth factor B-chain and platelet-derived growth factor β-receptor in fibroblasts of scleroderma. J Dermatol Sci 1998: 18: 90-97.
78. Rifkin D B, Moscatelli D. Recent developments in the cell biology of basic fibroblast growth factor. J Cell Biol 1989: 109: 1-6.
79. Chua C C, Chua B H, Zhao Z Y, Krebs C, Diglio C, Perrin E. Effect of growth factors on collagen metabolism in cultured human heart fibroblasts. Connect Tissue Res 1991: 26: 271-281.
80. Tan E M, Hoffren J, Rouda S et al. Decorin, versican, and biglycan gene expression by keloid and normal dermal fibroblasts: differential regulation by basic fibroblast growth factor. Exp Cell Res 1993: 209: 200-207.
81. Ichiki Y, Smith E A, LeRoy E C, Trojanowska M. Basic fibroblast growth factor inhibits basal and transforming growth factor-beta induced collagen alpha 2(I) gene expression in scleroderma and normal fibroblasts. J Rheumatol 1997: 24: 90-95.
82. Denton C P, Xu S, Black C M, Pearson J D. Scleroderma fibroblasts show increased responsiveness to endothelial cell-derived IL-1 and bFGF. J Invest Dermatol 1997: 108: 269-274.
83. Shinozaki M, Kawara S, Hayashi N, Kakinuma T, Igarashi A, Takehara K. Induction of subcutaneous tissue fibrosis in newborn mice by transforming growth factor β: simultaneous application with basic fibroblast growth factor causes persistent fibrosis. Biochem Biophys Res Commun 1997: 237: 292-296.
84. Mavilia C, Scaletti C, Romagnani P et al. Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 1997: 151: 1751-1758.
85. Postlethwaite A E, Holness M A, Katai H, Raghow R. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest 1992: 90: 1479-1485.
86. Makhluf H A, Stepniakowska J, Hoffman S, Smith E, LeRoy E C, Trojanowska M. IL-4 upregulates tenascin synthesis in scleroderma and healthy skin fibroblasts. J Invest Dermatol 1996: 107: 856-859.
87. Ihn H, Yamane K, Asano Y, Kubo M, Tamaki K. IL-4 up-regulates the expression of tissue inhibitor of metalloproteinase-2 in dermal fibroblasts via the p38 mitogen-activated protein kinase-dependent pathway. J Immunol 2002: 168: 1895-1902.
88. Elovic A E, Ohyama H, Sauty A et al. IL-4-dependent regulation of TGF-alpha and TGF-beta1 expression in human eosinophils. J Immunol 1998: 160: 6121-6127.
89. Seder R A, Marth T, Sieve MC et al. Factors involved in the differentiation of TGF-beta-producing cells from naive CD4+ T cells: IL-4 and IFN-gamma have opposite effects, while TGF-beta positively regulates its own production. J Immunol 1998: 160: 5719-5728.
90. Needlemann B W, Wigley F M, Stair R W. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor a, and interferon-γ levels in sera from patients with scleroderma. Arthritis Rheum 1985: 28: 775-780.
91. Serpier H, Gillery P, Salmon-Ehr V et al. Antagonistic effect of interferon-gamma and interleukin-4 on fibroblast cultures. J Invest Dermatol 1997: 109: 158-162.
92. Duncan M R, Berman B. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol 1991: 97: 686-692.
93. Feghali C A, Bost K L, Boulware D W, Levy L S. Human recombinant interleukin-4 induces proliferation and interleukin-6 production by cultured human skin fibroblasts. Clin Immunol Immunopathol 1992: 63: 182-197.
94. Macgaha T, Saito S, Phelps R G et al. Lack of skin fibrosis in tight skin (TSK) mice with targeted mutation in the interleukin-4Ra and transforming growth factor-β genes. J Invest Dermatol 2001: 116: 136-143.
95. Ong C J, Ip S, Teh S J et al. A role for T helper 2 cells in mediating skin fibrosis in tight-skin mice. Cell Immunol 1999: 196: 60-68.
96. Ong D, Wong C, Roberts C R, Teh H S, Jirik F R. Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma. Eur J Immunol 1998: 128: 2619-2629.
97. McGaha T L, Le M, Kodera T et al. Molecular mechanisms of interleukin-4-induced up-regulation of type I collagen gene expression in murine fibroblasts. Arthritis Rheum 2003: 48: 2275-2284.
98. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 1997: 24: 328-332.
99. Doucet C, Brouty-Boye D, Pottin-Clemenceau C, Jasmin C, Canonica G W, Azzarone B. IL-4 and IL-13 specifically increase adhesion molecule and inflammatory cytokine expression in human lung fibroblasts. Int Immunol 1998: 10: 1421-1433.
100. Oriente A, Fedarko N S, Pacocha S E, Huang S K, Lichtenstein L M, Essayan D M. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther 2000: 292: 988-994.
101. Lee C G, Homer R J, Zhu Z et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor β1. J Exp Med 2001: 194: 809-821.
102. Doucet C, Brouty-Boye D, Pottin-Clemenceau C, Canonica G W, Jasmin C, Azzarone B. Interleukin (IL)-4 and IL-13 act on human lung fibroblasts. J Clin Invest 1998: 101: 2129-2139.
103. Belperio J A, Dy M, Burdick M D et al. Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2002: 27: 419-427.
104. Hebbar M, Gillot J M, Hachulla E et al. Early expression of E-selectin, tumor necrosis factor a, and mast cell infiltration in the salivary glands of patients with systemic sclerosis. Arthritis Rheum 1996: 39: 1161-1165.
105. Piguet P F, Collart M A, Gran G E, Kapanci Y, Vassalli P. Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med 1989: 170: 655-663.
106. Murota H, Hamasaki Y, Nakashima T, Yamamoto K, Katayama I, Matsuyama T. Disruption of tumor necrosis factor receptor p55 impairs collagen turnover in experimentally induced sclerodermic skin fibroblasts. Arthritis Rheum 2003: 48: 1117-1125.
107. Fukasawa C, Kawaguchi Y, Harigai M et al. Increased CD40 expression in skin fibroblasts from patients with systemic sclerosis (SSc): role of CD40-CD154 in the phenotype of SSc fibroblasts. Eur J Immunol 2003: 33: 2792-2800.
108. Atamas S P, Luzina I G, Dai H, Wilt S G, White B. Synergy between CD40 ligation and Il-4 on fibroblast proliferation involves IL-4 receptor signaling. J Immunol 2002: 168: 1139-1145.
109. Kaufman J, Sime P J, Phipps R P. Expression of CD154 (CD40 ligand) by human lung fibroblasts: differential regulation by IFN-γ and IL-13, and implications for fibrosis. J Immunol 2004: 172: 1862-1871.
110. Reitamo S, Remitz A, Tamai K, Uitto J. Interleukin-10 modulates type I collagen and matrix metalloproteinase gene expression in cultured human skin fibroblasts. J Clin Invest 1994: 94: 2489-2492.
111. Yamamoto T, Eckes B, Krieg T. Effect of interleukin-10 on the gene expression of type I collagen, fibronectin, and decorin in human skin fibroblasts: differential regulation by transforming growth factor-β and monocyte chemoattractant protein-1. Biochem Biophys Res Commun 2001: 281: 200-205.
112. Matsumoto K, Nakamura T. Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int 2001: 59: 2023-2038.
113. Wu M-H, Yokozeki H, Takagawa S et al. Hepatocyte growth factor both prevents and ameliorates the symptoms of dermal sclerosis in a mouse model of scleroderma. Gene Ther 2004: 11: 170-180.
114. Leonard E J, Yoshimura T. Human monocyte chemoattractant protein-1 (MCP-1). Immunol Today 1990: 11: 97-101.
115. Gharaee-Kermani M, Denholm E M, Phan S H. Costimulation of fibroblast collagen and transforming growth factor β1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 1996: 271: 17779-17784.
116. Yamamoto T, Eckes B, Mauch C, Hartmann K, Krieg T. Monocyte chemoattractant protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL-1a loop. J Immunol 2000: 164: 6174-6179.
117. Yamamoto T, Eckes B, Krieg T. High expression and autoinduction of monocyte chemoattractant protein-1 in scleroderma fibroblasts. Eur J Immunol 2001: 31: 2936-2941.
118. Galindo M, Santiago B, Rivero M, Rullas J, Alcami J, Pablos J L. Chemokine expression by systemic sclerosis fibroblasts: abnormal regulation of monocyte chemoattractant protein 1 expression. Arthritis Rheum 2001: 44: 1382-1386.
119. Distler O, Pap T, Kowal-Bielecka O et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects of monocyte chemotaxis and collagen synthesis. Arthritis Rheum 2001: 44: 2665-2678.
120. Hasegawa M, Sato S, Takehara K. Augmentation of production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1a) and MIP-1β) in patients with systemic sclerosis: MCP-1 and MIP-1a may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 1999: 117: 159-165.
121. Yamamoto T, Eckes B, Hartmann K, Krieg T. Expression of monocyte chemoattractant protein-1 in the lesional skin of systemic sclerosis. J Dermatol Sci 2001: 26: 133-139.
122. Kawaguchi Y, Hara M, Wright T M. Endogenous IL-1α from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest 1999: 103: 1253-1260.
123. Zhu Z, Ma B, Zheng T et al. IL-13-induced chemokine responses in the lung: role of CCR2 in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol 2002: 168: 2953-2962.
124. Trautmann A, Toksoy A, Engelhardt E, Bröcker E B, Gillitzer R. Mast cell involvement in normal human skin wound healing: expression of monocyte chemoattractant protein-1 is correlated with recruitment of mast cells which synthesize interleukin-1 in vivo. I Pathol 2000: 190: 100-106.
125. Selvan R S, Butterfield J H, Krangel M S. Expression of multiple chemokine genes by human mast cells. J Biol Chem 1994: 269: 13893-13898.
126. Yamamoto T, Katayama I, Nishioka K. Expression of stem cell factor in the lesional skin of systemic sclerosis. Dermatology 1998: 197: 109-114.
127. Yamamoto T, Hartmann K, Eckes B, Krieg T. Role of stem cell factor and monocyte chemoattractant protein-1 in the interaction between fibroblasts and mast cels in fibrosis. J Dermatol Sci 2001: 26: 106-111.
128. Ong V H, Evans L A, Shiwen X et al. Monocyte chemoattractant protein 3 as a mediator of fibrosis: overexpression in systemic sclerosis and the type 1 tight-skin mouse. Arthritis Rheum 2003: 48: 1979-1991.
129. Yamamoto T, Nishioka K. Role of monocyte chemoattractant protein-1 and its receptor, CCR-2, in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol 2003: 121: 510-516.
130. Dong C, Zhus S, Wang T et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci USA 2002: 99: 3908-3913.
131. Keski-Oja J, Raghow R, Sawdey M et al. Regulation of mRNAs for type-1 plasminogen activator inhibitor, fibronectin, and type I procollagen by transforming growth factor-beta: divergent responses in lung fibroblasts and carcinoma cells. J Biol Chem 1988: 263: 3111-3115.
132. Eitzman D T, McCoy R D, Zheng X et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996: 97: 232-237.
133. Kikuchi K, Kadono T, Furue M, Tamaki K. Tissue inhibitor of metalloproteinase 1 (TIMP-1) may be an autocrine growth factor in scleroderma fibroblasts. J Invest Dermatol 1997: 108: 281-284.
134. Kikuchi K, Kubo M, Sato S, Fujimoto M, Tamaki K. Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosis. J Am Acad Dermatol 1995: 33: 973-978.
135. Toubi E, Kessel A, Grushko G, Sabo E, Rozenbaum M, Rosner I. The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity. Clin Exp Rheumatol 2002: 20: 221-224.
136. Kuroda K, Shinkai H. Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis. Arch Dermatol Res 1997: 289: 567-572.
137. Sambo P, Jannino L, Candela M et al. Monocytes of patients with systemic sclerosis (scleroderma) spontaneously release in vitro increased amounts of superoxide anion. J Invest Dermatol 1999: 112: 78-84.
138. Murrell G A C, Francis M J O, Bromley L. Modulation of fibroblast proliferation by oxygen free radicals. Biochem J 1990: 265: 659-665.
139. Falanga V, Martin T A, Takagi H et al. Low oxygen tension increases mRNA levels of alpha1(I) procollagen in human dermal fibroblasts. J Cell Physiol 1993: 157: 408-412.
140. Sambo P, Baroni S S, Luchetti M et al. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum 2001: 44: 2653-2664.
141. Oberley L W, Buettner G R. The production of hydroxyl radicals by bleomycin and iron(II). FEBS Lett 1979: 97: 47-49.
142. Yamamoto T, Takagawa S, Mizushima Y, Nishioka K. Effect of superoxide dismutase on bleomycin-induced dermal sclerosis: implications for the treatment of systemic sclerosis. J Invest Dermatol 1999: 113: 843-847.
143. Galindo M, Santiago B, Alcami J, Riyero M, Martin-Serrano J, Pablos J L. Hypoxia induces expression of the chemokines monocyte chemoattractant protein-1 (MCP-1) and IL-8 in human dermal fibroblasts. Clin Exp Immunol 2001: 123: 36-41.
144. Claman H N, Giorno R C, Seibold J R. Endothelial and fibroblast activation in scleroderma: the myth of the "uninvolved skin". Arthritis Rheum 1991: 34: 1495-1501.
145. Ishii H, Takada K. Bleomycin induces E-selectin expression in cultured umbilical vein endothelial cells by increasing its mRNA levels through activation of NF-κB/Rel. Toxicol Appl Pharmacol 2002: 184: 88-97.
146. Azuma A, Takahashi S, Nose M et al. Role of E-selectin in bleomycin induced lung fibrosis in mice. Thorax 2000: 55: 147-152.
147. Jelaska A, Korn J H. Role of apoptosis and transforming growth factor β1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum 2000: 43: 2230-2239.
148. Santiago B, Galindo M, Rivero M, Pablos J L. Decreased susceptibility to Fas-induced apoptosis of systemic sclerosis dermal fibroblasts. Arthritis Rheum 2001: 44: 1667-1676.
149. Sgonc R, Gruschwitz M S, Dietrich H, Recheis H, Gershwin M E, Wick G. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996: 98: 785-792.
150. Sgonc R, Dietrich H, Sieberer C, Wick G, Christner P J, Jimenez S A. Lack of endothelial cell apoptosis in the dermis of tight skin 1 and tight skin 2 mice. Arthritis Rheum 1999: 42: 581-584.
151. Yamamoto T, Nishioka K. Possible role of apoptosis in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol 2004: 122: 44-50.
152. Kuwano K, Hagimoto N, Kawasaki M et al. Essential role of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J Clin Invest 1999: 104: 13-19.
153. Buckley C D, Pilling D, Lord J M, Akbar A N, Scheel-Toellner D, Salmon M. Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol 2001: 22: 199-204.